[14] Topalian SL, Hodi FS, B rahmer JR, et al. Safety, activit Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low and immune correlates of anti- PD-l antiody in cancer[J) grade refractory/relapsed non-Hodgkin lymphoma [J Mol N Engl j Med,2012,366(26):2443-2454 Imaging biol,2010,12(2):198-203 [15 Kirkwood JM, Lorigan P, Hersey P,et al. Phase II trial of [25 Elliott DD, Sherman SI, Busaidy NL, et al. Growth factor tremelimumab(CP-675, 206)in patients with advanced re- receptors expression in anaplastic thyroid carcinoma: po- fractory or relapsed melanoma []. Clin Cancer Res ential markers for therapeutic stratification J]. Hum 2010,16(16):1042-1048. Pathol,2008,39(1):15-20 [16 Francisco LM, Sage PT, Sharpe AH. The PD-l pathwa [26] Chang WC, Chen JY, Lee CH,et al. Expression of decoy tolerance and autoimmunity [J]. Immunol Rev, 2010 ceptor 3 in diffuse sclerosing variant of papillary thyroid (1):219-242. M2 phage differentiation [17 Fourcade J, Sun Z, Pagliano O, et al. CD8(+)T cells spe and lymphatic invasion[J]. Thyroid, 2013, 23(6): 720-726 ific for tumor antigens can be rendered dysfunctional by [27] Guth AM, Hafeman SD, Elmslie RE, et al. Liposomal clo- the tumor microenvironment through upregulation of the donate treatment for tumour macrophage depletion inhibitory receptors BTLA and PD-1 [ J. Cancer Res dogs with soft-tissue sarcoma[J]. Vet Comp Oncol, 2013 2012,72(4):887-896 11(4):296 [18] Kollipara R, Schneider B, Radovich M, et al. Exceptional [28] Qian BZ, Li J, Zhang H,et al. CCL2 recruits inflamma response with immunotherapy in a patient with anaplastic tory monocytes to facilitate breast-tumour metastasis JI thyroid cancer[J]. Oncologist, 2017, 6(5): 407-414 Nature,2011,4757355):222-225 [19] Ahn S, Kim TH, Kim SW,et al. Comprehensive screening [29 Rolny C, Mazzone M, Tugues S,et al. HRG inhibits tumor for PD-Ll expression in thyroid cancer [J]. Endocr Relat growth and metastasis by inducing macrophage polariza Cancer,2017,24(2):97-106. tion and vessel normalization through downregulation of [20] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab GF[JI. Cancer Cell, 2011, 19(1): 31-44 versus docetaxel in patients with previously treated [30] Gogali F, Paterakis G, Rassidakis GZ, et al. Phenotypical small-cell lung cancer(OAK): a phase 3, open-label, multi- analysis of lymphocytes with suppressive and regulatory centre randomised controlled trial J]. Lancet, 2016, 389 properties (Tregs)and NK cells in the papillary carcinoma (10066):255-265 of thyroid (J. J Clin Endocrinol Metab, 2012, 97(5): 1474 [211 Rosenberg SA, Restifo NP. Adoptive cell transfer as per- sonalized immunotherapy for human cancer [J]. Science, [31] de Vries IJ, Castelli C, Huygens C, et al. Frequency of cir 2015,348(6230):62-68 ulating tregs with demethylated FOXP3 intron I [22 Sandri S, De SF, Lamolinara A, et al. Effective control of melanoma patients receiving tumor vaccines and poten- acute myeloid leukaemia and acute lymphoblastic tially Treg-depleting agents [J). Clin Cancer Res, 2011, 17 (4):841-848. ll therapy[. Oncotarget, 2017, 8(50): 86987-87001 [32] Balachandran VP, Cavnar MJ, Shan Z,et al. Imatinib po- [23] Weiner LM, Murray JC, Shuptrine CW. Antibody-based entiates antitumor T cell responses in gastrointestinal stro- immunotherapy of cancer! J) Cell, 2012, 148(6): 1081-1084. mal tumor through the inhibition of Ido [J]. Nat Med [24] lagaru A, Mittra ES, Ganjoo K, et al. 1311-Tositumomab 011,17(9):1094-1100 中国肿瘤2018年第27卷第5期 China caneer2018vol27No.5 363研究进展 21994-2018ChinaAcademicJournalElectronicPublishingHouse.Allrightsreservedhttp://www.cnki.net中国肿瘤 2018 年第 27 卷第 5 期 China Cancer,2018,Vol.27,N o.5 [14] Topalian SL，Hodi FS，B rahmer JR，et al.Safety，activity， and immune correlates of anti-PD-1 antiody in cancer[J]. N Engl J Med，2012，366(26)：2443-2454. [15] Kirkwood JM，Lorigan P，Hersey P，et al. Phase Ⅱ trial of tremelimumab(CP-675，206) in patients with advanced re￾fractory or relapsed melanoma [J]. Clin Cancer Res， 2010，16(16)：1042-1048. [16] Francisco LM，Sage PT，Sharpe AH. The PD-1 pathway in tolerance and autoimmunity [J]. Immunol Rev，2010，236 (1)：219-242. [17] Fourcade J，Sun Z，Pagliano O，et al. CD8 (+) T cells spe￾cific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 [J]. Cancer Res， 2012，72(4)：887-896. [18] Kollipara R，Schneider B，Radovich M，et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J]. Oncologist，2017，6(5)：407-414. [19] Ahn S，Kim TH，Kim SW，et al. Comprehensive screening for PD-L1 expression in thyroid cancer [J]. Endocr Relat Cancer，2017，24(2)：97-106. [20] Rittmeyer A，Barlesi F，Waterkamp D，et al. Atezolizumab versus docetaxel in patients with previously treated non￾small-cell lung cancer(OAK)：a phase 3，open-label，multi￾centre randomised controlled trial [J]. Lancet，2016，389 (10066)：255-265. [21] Rosenberg SA，Restifo NP. Adoptive cell transfer as per￾sonalized immunotherapy for human cancer [J]. Science， 2015，348(6230)：62-68. [22] Sandri S，De SF，Lamolinara A，et al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T￾cell therapy[J]. Oncotarget，2017，8(50)：86987-87001. [23] Weiner LM，Murray JC，Shuptrine CW. Antibody-based immunotherapy of cancer[J]. Cell，2012，148(6)：1081-1084. [24] Iagaru A，Mittra ES，Ganjoo K，et al. 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low￾grade refractory/relapsed non-Hodgkin lymphoma [J]. Mol Imaging Biol，2010，12(2)：198-203. [25] Elliott DD，Sherman SI，Busaidy NL，et al. Growth factor receptors expression in anaplastic thyroid carcinoma：po￾tential markers for therapeutic stratification [J]. Hum Pathol，2008，39(1)：15-20. [26] Chang WC，Chen JY，Lee CH，et al. Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma：correlation with M2 macrophage differentiation and lymphatic invasion[J]. Thyroid，2013，23(6)：720-726. [27] Guth AM，Hafeman SD，Elmslie RE，et al. Liposomal clo￾dronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma[J]. Vet Comp Oncol，2013， 11(4)：296. [28] Qian BZ，Li J，Zhang H，et al. CCL2 recruit’s inflamma￾tory monocytes to facilitate breast-tumour metastasis [J]. Nature，2011，475(7355)：222-225. [29] Rolny C，Mazzone M，Tugues S，et al. HRG inhibits tumor growth and metastasis by inducing macrophage polariza￾tion and vessel normalization through downregulation of PlGF[J]. Cancer Cell，2011，19(1)：31-44. [30] Gogali F，Paterakis G，Rassidakis GZ，et al. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid[J]. J Clin Endocrinol Metab，2012，97(5)：1474- 1482. [31] de Vries IJ，Castelli C，Huygens C，et al. Frequency of cir￾culating tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and poten￾tially Treg-depleting agents [J]. Clin Cancer Res，2011，17 (4)：841-848. [32] Balachandran VP，Cavnar MJ，Shan Z，et al. Imatinib po￾tentiates antitumor T cell responses in gastrointestinal stro￾mal tumor through the inhibition of Ido [J]. Nat Med， 2011，17(9)：1094-1100. 363 研究进展